Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.45 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27559091 | 0.99 | MEN1 (0.45) | MEN1KMT2AMAPTCYP19A1AR | |
| SCHEMBL6736474 | 0.90 | MEN1 (0.46) | MEN1KMT2AMAPTCYP19A1AR | |
| SCHEMBL6738421 | 0.85 | CYP19A1 (0.44) | MEN1KMT2AMAPTCYP19A1AR | |
| SCHEMBL6660357 | 0.83 | MAPT (0.49) | MEN1KMT2AMAPTCYP19A1POLB | |
| SCHEMBL8799741 | 0.81 | MEN1 (0.47) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL27559095 | 0.81 | AR (0.50) | MEN1KMT2AMAPTCYP19A1AR | |
| SCHEMBL6736399 | 0.78 | NT5E (0.40) | MEN1KMT2AMAPTPOLBLMNA | |
| SCHEMBL344718 | 0.77 | ALOX5 (0.50) | MEN1KMT2AARLMNA | |
| SCHEMBL31440585 | 0.76 | MAPT (0.53) | MEN1KMT2AMAPTCYP19A1AR | |
| SCHEMBL7201567 | 0.74 | CYP19A1 (0.43) | MEN1KMT2AMAPTCYP19A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790978-B2 | 4-HYDROXY-3-ARYLSULFONYL, 3-AMINOSULFONYL OR 3-AMINOCARBONYL-PHENOXYANILINOCARBONYL-OPTIONAL ALKYLENE-CARBOXYLIC ACID OR CARBONYL-5-TETRAZOLES | NOVARTIS AG (CH) | 2004-09-14 | — | — | US | disclosed |
| US-6689896-B2 | AMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2004-02-10 | — | — | US | disclosed |
| US-6599942-B1 | Method of lowering LDL cholesterol and Lipoprotein a levels in mammals using such compounds | NOVARTIS AG (CH) | 2003-07-29 | — | — | US | disclosed |
| US-20020107390-A1 | Thyromimetic organic compounds | KUKKOLA PAIVI J (US) | 2002-08-08 | — | — | US | disclosed |
| US-20020045751-A1 | Thyromimetic organic compounds | NOVARTIS AG (CH) | 2002-04-18 | — | — | US | disclosed |
| EP-1165502-A1 | DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058279-A1 | DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045751-A1 | Thyromimetic organic compounds | TPO, THRA, LPO | MEN1 2950/4885KMT2A 2116/4885MAPT 3417/4885 |
| US-20020107390-A1 | Thyromimetic organic compounds | TSHR, NR1H3, NR1H2 | MEN1 4133/4885KMT2A 3493/4885MAPT 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.